Cantor Fitzgerald Reiterates “Neutral” Rating for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “neutral” rating reissued by Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports. They currently have a $36.00 target price on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 9.72% from the company’s current price.

Supernus Pharmaceuticals Stock Up 0.4 %

Shares of NASDAQ SUPN opened at $32.81 on Wednesday. The stock’s 50-day simple moving average is $37.34 and its two-hundred day simple moving average is $35.39. Supernus Pharmaceuticals has a twelve month low of $25.53 and a twelve month high of $40.28. The firm has a market capitalization of $1.81 billion, a P/E ratio of 30.66 and a beta of 0.90.

Insider Activity at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. This represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock valued at $440,263 over the last three months. 9.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in SUPN. Barclays PLC raised its holdings in shares of Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after buying an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC bought a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $791,000. Geode Capital Management LLC raised its stake in shares of Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $987,000 after acquiring an additional 2,121 shares during the last quarter. Finally, Empowered Funds LLC bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $1,498,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.